Glucocorticoids

Overview

Endogenous Physiology

• Hypothalamus releases corticotropin-releasing hormone (CRH)
• Anterior pituitary releases ACTH
• Adrenal cortex releases cortisol, which feeds back to suppress both CRH and ACTH

Structure-Activity Relationships

• Adding a double bond in ring A (prednisone/prednisolone) enhances glucocorticoid activity without increasing mineralocorticoid activity
• 6α methylation produces methylprednisolone (further increases glucocorticoid activity)
• 9α fluorination yields triamcinolone
• Both 6α methylation and 9α fluorination together yield dexamethasone

Potency Comparison

Mechanism of Action

Genomic Pathways

1. cGCR-mediated genomic mechanism (Pathway I): Glucocorticoids are lipophilic and freely cross the cell membrane. In the cytosol, they bind to the cytosolic glucocorticoid receptor (cGCR), which is held in an inactive state by heat shock proteins (HSP90, HSP70) and Src kinase. Ligand binding causes dissociation of the chaperone complex. The glucocorticoid-receptor complex is chaperoned to the nucleus, where it binds to glucocorticoid response elements (GREs) in gene promoters or suppressors to activate or repress transcription.
2. Transrepression via NF-κB and AP-1: The glucocorticoid-receptor complex directly inhibits key pro-inflammatory transcription factors - NF-κB and AP-1 - thereby suppressing transcription of genes encoding cytokines (IL-1, IL-6, TNF-α), COX-2, iNOS, and adhesion molecules. This is considered a primary anti-inflammatory mechanism.
3. cGCR-mediated nongenomic mechanism (Pathway II): Released Src kinase from the HSP complex triggers rapid cytoplasmic signaling independently of gene transcription.

Nongenomic Pathways

1. Membrane glucocorticoid receptor (mGCR, Pathway III): Glucocorticoids bind membrane-associated receptors, producing rapid effects within seconds to minutes.
2. Nonspecific membrane effects (Pathway IV): High-dose glucocorticoids intercalate into cell membranes, altering membrane biophysics. This is the likely basis for the pronounced nongenomic effects of IV pulse methylprednisolone (which has >3-fold more nongenomic effects than prednisolone at equivalent doses).

Anti-Inflammatory and Immunological Effects

• Inhibit pro-inflammatory cytokines: IL-1β, IL-2, IL-6, IL-8, TNF-α, IFN-γ
• Inhibit pro-inflammatory enzymes: COX-2, phospholipase A2 (via lipocortin-1/annexin A1 induction), collagenase, elastase, plasminogen activator
• Decrease T-cell function and reduce circulating T-cell numbers
• Inhibit Fc receptor expression, reducing clearance of antibody-coated blood cells
• Increase circulating neutrophils (demargination from vessel walls) while impairing their migration to sites of inflammation
• Inhibit leukocyte adhesion to endothelial cells

Dosing Concepts

• Low dose: ≤7.5 mg/day
• Medium dose: >7.5 to ≤30 mg/day
• High dose: >30 to ≤100 mg/day
• Very high / pulse therapy: 250-1000 mg/day IV methylprednisolone for 3 days (for life- or organ-threatening disease)

Therapeutic Uses

Adverse Effects

Key Adverse Effects (dose-dependent)

• Glucocorticoid-induced osteoporosis (GIOP): The most devastating long-term complication. Up to 40% of users develop bone loss leading to fracture. Predominantly affects trabecular bone initially (vertebrae), later cortical bone (femoral neck). First-year bone loss can be 1.5-20% at ≤10 mg/day. Risk mitigation requires calcium/vitamin D supplementation and bisphosphonate therapy.
• Proximal myopathy: Muscle weakness, particularly in the thighs and shoulder girdle

• Hyperglycemia / steroid-induced diabetes mellitus
• Central (centripetal) obesity, moon facies, buffalo hump (Cushing-like features)
• Hypertriglyceridemia
• Negative calcium balance

• Hypertension (sodium and water retention)
• Peripheral edema

• Increased susceptibility to infection (bacterial, fungal, viral)
• Impaired wound healing

• HPA axis suppression (adrenal suppression) - risk of adrenal crisis on withdrawal
• Diminished sex hormone production

• Euphoria, emotional disturbances, depression, psychosis
• Insomnia

• Posterior subcapsular cataracts
• Glaucoma (raised intraocular pressure)

• Growth retardation (mechanism unknown, partly via growth hormone suppression; alternate-day dosing reduces this effect)

• Skin atrophy, ecchymosis, striae, telangiectasia

Discontinuation and Adrenal Suppression

• Doses must be tapered slowly according to individual tolerance
• Risk is present any time the HPA axis has been suppressed (typically courses >3 weeks or doses above physiologic replacement)
• Patients on chronic steroids may need stress dosing (increased dose) during surgery or serious illness

Drug Interactions

• Phenobarbital, phenytoin, rifampin: Induce CYP3A4, increasing glucocorticoid metabolism and reducing efficacy
• Concurrent aspirin: Accelerates salicylate metabolism, reducing salicylate levels
• NSAIDs: Additive GI risk (peptic ulceration)
• Antidiabetic drugs: Glucocorticoids antagonize their effects, requiring dose adjustments

Special Considerations

Glucocorticoids - Physiology

1. The Adrenal Gland: Source of Glucocorticoids

2. Biosynthesis: From Cholesterol to Cortisol

1. Circulating LDL taken up by receptor-mediated endocytosis (quantitatively dominant)
2. De novo synthesis from acetate

Five key enzymatic steps (zona fasciculata):

1. Cholesterol → Pregnenolone (mitochondria): Side-chain cleavage enzyme (P-450scc / 20,22-desmolase) removes carbons 22-27. This is the rate-limiting step.
2. Pregnenolone → Progesterone (SER): 3β-HSD oxidizes the hydroxyl group at C-3 to a ketone.
3. Progesterone → 17α-Hydroxyprogesterone (SER): 17α-hydroxylase (P-450c17/CYP17) adds -OH at C-17.
4. 17α-Hydroxyprogesterone → 11-Deoxycortisol (SER): 21α-hydroxylase (P-450c21/CYP21A2) adds -OH at C-21.
5. 11-Deoxycortisol → Cortisol (mitochondria): 11β-hydroxylase (P-450c11/CYP11B1) adds -OH at C-11.

Key enzyme absent from zona glomerulosa: 17α-hydroxylase is not substantially present in the glomerulosa, which is why that zone cannot make cortisol and instead makes aldosterone (using aldosterone synthase/CYP11B2). (Medical Physiology)

Clinical relevance - 21α-hydroxylase deficiency (most common congenital adrenal enzyme defect): Blocks synthesis of both cortisol and aldosterone. The resulting low cortisol removes negative feedback → ACTH rises → drives excessive production of adrenal androgens. Clinically: salt-wasting, hypoglycemia, and virilization (ambiguous genitalia in female infants).

3. Transport and Metabolism

• ~90% of circulating cortisol is protein-bound:
  • ~75% bound to corticosteroid-binding globulin (CBG / transcortin) - high affinity, low capacity
  • ~15% loosely bound to albumin
  • Only ~10% is free (biologically active)
• Synthetic glucocorticoids (dexamethasone, betamethasone, triamcinolone) have <1% affinity for CBG - they circulate largely free, contributing to greater biological activity per dose.
• Cortisol is metabolized in the liver. Prednisone (prodrug) requires hepatic conversion to active prednisolone by 11β-HSD. In severe liver disease, prednisolone is preferred over prednisone. (Rheumatology, 2-Volume Set)
• The enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) inactivates cortisol to cortisone in tissues like the kidney, protecting mineralocorticoid receptors from activation by cortisol (which has equal affinity for the mineralocorticoid receptor). Liquorice inhibits 11β-HSD2, causing apparent mineralocorticoid excess.

4. The HPA Axis: Regulation of Cortisol Secretion

Hypothalamus (paraventricular nucleus)
        ↓ CRH (41-amino acid neuropeptide)
Anterior Pituitary (corticotroph cells)
        ↓ ACTH (39-amino acid peptide)
Adrenal Cortex (zona fasciculata)
        ↓ Cortisol
⟲ Negative feedback → inhibits CRH & ACTH

CRH (Corticotropin-Releasing Hormone)

• Secreted by small-bodied neurons of the paraventricular nucleus (PVN) of the hypothalamus
• Released into the hypophyseal portal venous plexus → reaches anterior pituitary
• Binds CRH-R1 (GPCR) on corticotrophs → Gαs → ↑cAMP → PKA → opens L-type Ca²⁺ channels → exocytosis of pre-formed ACTH
• Over longer time: increases POMC gene transcription
• Arginine vasopressin (AVP) is a co-secretagogue from the PVN that potentiates CRH-induced ACTH release (important during stress involving dehydration or trauma)

ACTH (Adrenocorticotropic Hormone)

• A 39-amino acid peptide secreted by anterior pituitary corticotrophs
• Derived from pro-opiomelanocortin (POMC), a large precursor that also yields:
  • β-lipotropin (β-LPH)
  • α-MSH, γ-MSH (melanocyte-stimulating hormones - cause skin hyperpigmentation in Addison's disease via excess ACTH/POMC)
  • CLIP (corticotropin-like intermediate lobe peptide)
  • β-endorphin
• ACTH acts on adrenal fasciculata cells to stimulate cholesterol uptake and activate the rate-limiting step (P-450scc), rapidly driving cortisol synthesis
• Chronic ACTH excess causes adrenal hyperplasia; chronic ACTH deficiency causes adrenal atrophy

Negative Feedback

1. Anterior pituitary: Cortisol binds cytosolic GR → nucleus → binds GREs → inhibits POMC transcription and blocks synthesis of the CRH receptor; also inhibits release of pre-formed ACTH from vesicles.
2. Hypothalamus: Cortisol decreases CRH mRNA levels in PVN neurons and inhibits release of pre-formed CRH (less dominant than pituitary feedback).

5. Circadian Rhythm and Pulsatility

• ACTH secretory activity is greatest in the early morning and lowest late afternoon/evening
• Cortisol peaks at ~16 μg/dL around 8 AM and falls to near zero by midnight
• The rhythm is driven by the suprachiasmatic nucleus (receives retinal light input) - blind individuals lose circadian rhythms
• Superimposed on the circadian rhythm is pulsatile secretion driven by pulsatile CRH release
• ACTH pulses are sharper and briefer (shorter half-life); cortisol oscillations are broader and damped

6. Stress Response

• Hypoglycemia → stimulates CRH and ACTH → ↑cortisol → gluconeogenesis raises blood glucose
• Physical trauma, infection, surgery, major illness → activate ascending noradrenergic pathways → stimulate PVN CRH neurons
• The amplitude of CRH secretory bursts increases during stress (not frequency)
• Chronic stress → chronic ACTH elevation → adrenal hypertrophy
• Glucocorticoids are sometimes called "stress hormones" because they allow the body to cope with acute threats - but chronic activation is harmful

7. Physiological Actions of Cortisol

A. Carbohydrate Metabolism - "Diabetogenic"

• ↑ Gluconeogenesis in liver (key survival function during fasting)
• ↑ Protein catabolism in muscle → provides amino acids to liver as gluconeogenic substrates
• ↑ Lipolysis → provides glycerol to liver for gluconeogenesis; free fatty acids used as alternative fuel
• ↓ Glucose utilization by peripheral tissues (antagonizes insulin action)
• ↓ Insulin sensitivity of adipose tissue

In hypocortisolism (Addison's disease): hypoglycemia In hypercortisolism (Cushing's syndrome): hyperglycemia (Costanzo Physiology)

B. Protein Metabolism

• Catabolic in muscle, bone, connective tissue, skin - mobilizes amino acids
• Anabolic in the liver - stimulates synthesis of enzymes for gluconeogenesis
• Net effect of prolonged excess: muscle wasting, skin thinning, striae, poor wound healing

C. Fat Metabolism - Redistribution

• Excess cortisol causes characteristic fat redistribution:
  • ↑ Fat deposition: face (moon facies), trunk, supraclavicular, dorsal interscapular (buffalo hump)
  • ↓ Fat in extremities
• Mechanism: differential insulin sensitivity across fat depots; visceral fat is more glucocorticoid-sensitive

D. Anti-Inflammatory Actions

1. Induces lipocortin (annexin A1) - inhibits phospholipase A2, blocking release of arachidonic acid from membrane phospholipids → suppresses prostaglandin and leukotriene synthesis
2. Inhibits IL-2 production and T lymphocyte proliferation
3. Inhibits histamine and serotonin release from mast cells and platelets

E. Immune Suppression

• Suppresses cellular immunity via T-cell inhibition (IL-2 ↓)
• Reduces Fc receptor expression on macrophages
• Promotes neutrophilia (demargination from vessel walls) while impairing neutrophil migration to inflammatory sites
• Basis for glucocorticoid use in transplant rejection and autoimmune diseases

F. Cardiovascular - Permissive Role

• Up-regulates α₁-adrenergic receptors on arterioles (permissive effect)
• Allows arterioles to respond normally to catecholamines (norepinephrine, epinephrine)
• Without cortisol → hypotension (hallmark of Addison's disease - refractory to vasopressors)
• Excess cortisol → hypertension (Cushing's syndrome)

G. Bone and Calcium Metabolism

• Decreases synthesis of type I collagen (major bone matrix component)
• Decreases osteoblast function (bone formation ↓)
• Decreases intestinal Ca²⁺ absorption (interferes with vitamin D action)
• Net result: negative calcium balance and osteoporosis with chronic excess

H. Renal Effects

• Increases GFR by causing afferent arteriole vasodilation → ↑ renal blood flow
• Without cortisol, GFR falls; excess cortisol can contribute to hypertension via this mechanism and via sodium retention (weak mineralocorticoid effect of cortisol)

I. CNS Effects

• Glucocorticoid receptors are widely distributed in the CNS (hippocampus, prefrontal cortex, hypothalamus)
• Normal cortisol: needed for normal mood, cognition, and arousal
• Excess cortisol: euphoria, emotional lability, depression, psychosis, insomnia, decreased REM sleep
• Deficiency: fatigue, depression, cognitive impairment

8. Summary Table: Physiological Actions of Glucocorticoids

9. Clinical Correlates

Lung Surfactant

1. Historical Discovery

2. The Physics: Surface Tension and the Law of Laplace

The Law of Laplace

• P = distending pressure
• T = surface tension of the lining fluid
• r = radius of the alveolus

Why Surfactant Prevents Pulmonary Edema

3. What Surfactant Does: Functional Summary

4. Composition of Surfactant

• ~85% phospholipids
• ~5% neutral lipids (cholesterol, free fatty acids)
• ~10% proteins (four surfactant-specific proteins: SP-A, SP-B, SP-C, SP-D)

Phospholipid Composition (Murray & Nadel's Textbook of Respiratory Medicine, Table 3.2)

DPPC - The Critical Lipid

5. The Surfactant Proteins

SP-A (Surfactant Protein A)

• Most abundant surfactant protein
• A large secreted octadecameric collagenous glycoprotein forming a "bouquet-like" structure of 18 monomers (6 trimers)
• Contains a C-type lectin / carbohydrate recognition domain (CRD) - recognizes carbohydrates on pathogens
• Primary role: innate immunity - not biophysical activity
  • Opsonizes bacteria, viruses, fungi
  • Regulates cytokine production in macrophages (suppresses inflammation in health; enhances it during infection - the "inflammatory paradox")
  • Regulates feedback uptake/recycling of surfactant by AT2 cells
• Together with SP-B, needed for formation of tubular myelin (an organized extracellular surfactant intermediate)
• Member of the collectin family (like mannose-binding lectin, C1q)
• Two human genes: SFTPA1 and SFTPA2 on chromosome 10

SP-B (Surfactant Protein B)

• Extremely hydrophobic (18-kDa disulfide-linked homodimer); residues predominantly valine and leucine
• Member of the saposin-like peptide family
• Critical for biophysical surfactant activity:
  • Promotes adsorption and surface spreading of phospholipids onto the air-liquid interface
  • Enables DPPC to form the stable monomolecular film
  • Essential for formation of lamellar bodies (LBs) within AT2 cells - the storage organelles for surfactant
  • Required for processing of SP-C (see below)
• SP-B deficiency is uniformly fatal (or requires lung transplantation): homozygous loss-of-function mutations cause absence of both SP-B and SP-C, since SP-B is required for LB formation and thus posttranslational processing of the SP-C proprotein
• Encoded by the SFTPB gene on chromosome 2

SP-C (Surfactant Protein C)

• Extremely hydrophobic 4.2-kDa mature peptide; only ~1% of total surfactant protein by mass
• Works together with SP-B to orient DPPC within the surfactant film and maintain the thin film layer
• Encoded by SFTPC on chromosome 8
• Complex processing: synthesized as a 21-kDa proprotein (proSP-C), processed through the ER, Golgi, and multivesicular bodies into the mature form stored in lamellar bodies
• Mutations in SFTPC (especially in the BRICHOS domain) cause misfolding, ER retention, and are linked to familial interstitial lung disease (ILD) and pulmonary fibrosis in adults and children

SP-D (Surfactant Protein D)

• Hydrophilic collectin glycoprotein, structurally similar to SP-A
• Primary role: host defense (not biophysical)
  • Binds to Gram-negative bacteria, fungi, and other pathogens
  • Binds lipopolysaccharide (LPS)
  • Modulates innate immune and inflammatory responses to inhaled antigens and acute lung injury
• Works with SP-A to organize SP-B and SP-C into the surfactant layer
• Gene located on chromosome 10 near SFTPA1 and SFTPA2

6. The Type II Pneumocyte and Lamellar Bodies

• Cuboidal cells found at alveolar corners (accounting for only ~5% of alveolar surface area but ~60% of alveolar cells by number)
• Characterized by distinctive lamellar bodies (LBs) - electron-dense lysosome-related organelles that store packaged surfactant as densely stacked phospholipid bilayers
• Lamellar bodies require SP-B for their formation
• Upon stimulation, lamellar bodies fuse with the plasma membrane and are secreted by exocytosis into the alveolar space
• After secretion, lamellar body contents unroll into an extracellular structured form called tubular myelin (an organized lattice of surfactant bilayers at right angles), which serves as a reservoir for rapid replenishment of the surface monolayer during inspiration
• Surfactant is cleared from the alveolar space by:
  1. Re-uptake by AT2 cells (major route) - regulated by SP-A
  2. Macrophage phagocytosis
  3. Mucociliary clearance

Hormonal Regulation of Synthesis

7. Clinical Conditions

A. Neonatal Respiratory Distress Syndrome (NRDS / Infant RDS / Hyaline Membrane Disease)

• Most common cause of respiratory insufficiency in newborns
• ~60% of infants born at <28 weeks gestation
• ~30% born at 28-34 weeks gestation
• <5% born after 34 weeks gestation
• Additional risk factors: male sex, maternal diabetes, cesarean section before labor onset

• Lungs are normal size but heavy and airless, with mottled purple color
• Microscopy: diffuse atelectasis with characteristic eosinophilic hyaline membranes lining respiratory bronchioles, alveolar ducts, and alveoli
• Survivors show type II pneumocyte proliferation and interstitial fibrosis as reparative changes

1. Antenatal corticosteroids (betamethasone/dexamethasone) given to mother at 24-34 weeks threatened preterm delivery → stimulates fetal surfactant synthesis → reduces RDS incidence and severity
2. Exogenous surfactant replacement (intratracheal) at birth: natural (poractant alfa from porcine lungs, beractant from bovine lungs) or synthetic preparations
3. Positive pressure ventilation / CPAP (continuous positive airway pressure) to maintain alveolar patency

B. Adult/Acute Respiratory Distress Syndrome (ARDS)

• Edema fluid containing serum proteins (albumin, globulin, fibrinogen, CRP) leaks into the alveolar space and competitively inhibits surfactant adsorption and film formation
• Phospholipases A2 and C released during lung injury degrade surfactant phospholipids
• Oxidants (reactive oxygen species, peroxynitrite) from activated alveolar macrophages damage both surfactant lipids and proteins
• Inflammatory cytokines (TNF-α, TGF-β1) suppress SP-A, SP-B, SP-C synthesis in AT2 cells
• Exogenous surfactant has been effective in animal models but has not shown consistent benefit in clinical ARDS trials (unlike NRDS); current treatment focuses on lung-protective ventilation and prone positioning

C. Inherited Surfactant Disorders

D. Pulmonary Alveolar Proteinosis (PAP)

• Characterized by accumulation of surfactant-like material (PAS-positive) in alveoli
• Most common form (autoimmune PAP): GM-CSF autoantibodies impair alveolar macrophage function → macrophages cannot clear surfactant → alveolar flooding
• CT: characteristic "crazy paving" pattern
• Treatment: whole-lung lavage; inhaled or systemic GM-CSF

8. Surfactant Inhibition

Quick Reference Summary

Embryology of Somites

1. Overview

2. Timeline: From Gastrulation to Somite Formation

3. Origin: Paraxial Mesoderm

Midline (notochord)
    │
    ├── Paraxial mesoderm ← SOMITES form here
    │        (thick, bilateral columns)
    │
    ├── Intermediate mesoderm ← urogenital system
    │        (thinner)
    │
    └── Lateral mesoderm ← body wall, gut wall, coelom
             (thinnest; splits into somatic + splanchnic layers)

4. Somite Numbers by Region

5. The Molecular Segmentation Clock ("Clock and Wavefront" Model)

The "Clock and Wavefront" Model (Cooke & Zeeman, 1970s)

• The clock is a wave of oscillating gene expression that sweeps from the caudal tail bud rostrally through the PSM. Each sweep "pinches off" one new pair of somites.
• The wavefront is a threshold of signaling activity (FGF8 and WNT gradients, high caudally) that determines where in the PSM the clock oscillation is interpreted as a boundary.
• As the embryo elongates caudally, the wavefront moves caudally too, allowing new somites to form progressively.

Key Molecular Players

6. Somite Structure: Epithelial-to-Mesenchymal Transitions

SOMITE (epithelial sphere)
        │
        ├─── SCLEROTOME (ventromedial) ──────► Vertebrae & ribs
        │         (epithelial → mesenchymal)
        │
        └─── DERMOMYOTOME (dorsolateral) ────► remains epithelial
                  │
                  ├── MYOTOME ─────────────────► Skeletal muscle
                  │
                  └── DERMATOME ───────────────► Dermis (back skin)

Signaling that Drives Differentiation

7. Somite Derivatives in Detail

A. Sclerotome → Axial Skeleton

• Vertebral bodies are intersegmental - they bridge two adjacent somitic segments
• The spinal nerve (derived from the neural tube at the level of one somite) therefore exits between two vertebrae, running through the center of the original sclerotome
• The intervertebral disc forms at the junction between the cranial and caudal halves of a sclerotome
• The nucleus pulposus of the disc is a remnant of the notochord (which normally disappears as it is surrounded by vertebral bodies)

• Vertebral bodies and arches
• Ribs (from thoracic sclerotomes)
• Sternum (from sternal bars of lateral plate mesoderm - not directly from somites)
• Intervertebral discs

B. Dermomyotome → Myotome and Dermatome

Myotome (muscle precursors)

• Persists in: deep intrinsic back muscles (rotatores, interspinales, intertransverse muscles), intercostal muscles
• Disappears (polymerization) in: superficial back muscles (which span multiple segments); but the segmental neurovascular supply remains as evidence of origin

Dermatome (dermis of back)

8. Complete Summary of Somite Derivatives

PARAXIAL MESODERM (presomitic → somites)
│
├── SCLEROTOME (ventromedial)
│       ├── Vertebral bodies (via resegmentation)
│       ├── Vertebral arches (pedicles, laminae, spinous/transverse processes)
│       ├── Ribs (thoracic levels)
│       └── Nucleus pulposus contribution (notochordal remnant encased by sclerotome)
│
└── DERMOMYOTOME (dorsolateral)
        │
        ├── MYOTOME
        │       ├── Epaxial → intrinsic back muscles (dorsal ramus)
        │       └── Hypaxial → body wall muscles, diaphragm, limb muscles (ventral ramus)
        │
        └── DERMATOME → dermis of the back

9. Clinical Correlations

Spondylocostal Dysostosis (Jarcho-Levin Syndrome)

• DLL3 (Delta-like-3)
• MESP2 (Mesoderm posterior-2)
• LFNG (Lunatic fringe)
• HES7
• TBX6 (also dominant forms)

Hemivertebra

Spina Bifida

Klippel-Feil Syndrome

Nucleus Pulposus Herniation (Disc Prolapse)

Alagille Syndrome

Presenilin-1 Mutations

10. Quick Reference Summary

Periodic Breathing

1. Definition

2. The Physiology: Why Breathing Oscillates

Normal Respiratory Control

• Central chemoreceptors (medullary) - primarily sense PCO₂/H⁺; high sensitivity, slow response
• Peripheral chemoreceptors (carotid and aortic bodies) - sense PO₂, PCO₂, pH; faster response, primarily hypoxia detectors

The Concept of "Loop Gain"

• Loop gain < 1: System is stable; a perturbation is damped and breathing returns to normal
• Loop gain > 1: System is unstable; a perturbation is amplified, causing sustained oscillation → periodic breathing

1. High controller gain (exaggerated chemoreceptor sensitivity to CO₂/O₂)
2. Long circulation time (delayed feedback from lungs to chemoreceptors)
3. Low lung/body CO₂ stores (small CO₂ buffer capacity → larger PCO₂ swings per breath)
4. Proximity of PaCO₂ to the apneic threshold (the PCO₂ level below which breathing ceases)

3. The Experimental Model: Hyperventilation-Induced Periodic Breathing

1. Forced hyperventilation → ↑ alveolar PO₂, ↓ alveolar PCO₂ (CO₂ blown off)
2. Breathing stops voluntarily → PCO₂ is now below the apneic threshold → apnea
3. During apnea: ↓ alveolar PO₂, ↑ alveolar PCO₂ (gas exchange continues without ventilation)
4. Hypoxia stimulates carotid body chemoreceptors before PCO₂ returns to normal
5. A few breaths occur (hyperpnea) → the hypoxic stimulus is eliminated → apnea again
6. This cycle repeats, gradually dampening as PCO₂ normalizes
7. Eventually PCO₂ returns to normal and stable breathing resumes

Key proof: This apnea does NOT occur if hyperventilation is done with a 5% CO₂ mixture (which prevents the fall in PCO₂), confirming that CO₂ depletion below the apneic threshold is the driver. (Ganong's Review of Medical Physiology)

4. The Apneic Threshold

5. Cheyne-Stokes Respiration (CSR)

Pattern

• Repetitive cycles of crescendo-decrescendo hyperpnea followed by central apnea
• Cycle length: 40-90 seconds (longer than altitude-related periodic breathing)
• Predominantly occurs during non-REM sleep (rare in REM sleep)
• Arousals occur at the peak of hyperpnea (not at apnea termination - this distinguishes it from OSA)

Conditions Associated with CSR

Two Mechanisms in Heart Failure

• In CHF, reduced cardiac output → prolonged lung-to-brain circulation time (normally ~30-40 s; in CHF may be >60-90 s)
• When the lungs hyperventilate and lower PCO₂, the blood with low PCO₂ takes abnormally long to reach the medullary and carotid chemoreceptors
• During this delay, the lungs continue to over-ventilate, lowering PCO₂ even further
• When the hypocapnic blood finally arrives at the brainstem → apnea
• During apnea, PCO₂ builds up again and the cycle repeats
• The cycle length of CSR in heart failure is longer than altitude-related periodic breathing precisely because circulation time is prolonged

• Some heart failure patients have increased responsiveness to CO₂ (disrupted inhibitory neural pathways)
• A small rise in PCO₂ triggers an exaggerated hyperpnea, which drives PCO₂ far below the apneic threshold → apnea
• When PCO₂ rises back to normal, the overly sensitive system again over-responds → cycling continues

CSR as a Prognostic Marker in Heart Failure

• CSR independently increases the risk of premature death by ~150% in HFrEF patients (observational data)
• Time with SaO₂ <90% (T90) predicts mortality in a dose-dependent manner (~16% increased risk per hour below 90%)
• Both CSA and OSA cause sustained sympathetic overactivation (hyperadrenergic state), worsening cardiac remodeling
• CSA is associated with hospital readmissions and worse outcomes
• Risk factors for CSR in HF: male sex, age >65, atrial fibrillation, awake hypocapnia (PaCO₂ <38 mmHg)

6. High-Altitude Periodic Breathing

Mechanism

1. Hypoxia at altitude stimulates peripheral chemoreceptors → hyperventilation
2. Hyperventilation lowers PaCO₂ → hypocapnia
3. PaCO₂ falls below the apneic threshold (especially during sleep) → central apnea
4. During apnea: PaO₂ falls further, PaCO₂ rises → peripheral chemoreceptors re-stimulated
5. Burst of hyperventilation → PaCO₂ falls again below apneic threshold → next apnea

Features

• Cycle time: 12-34 seconds (short - because at altitude, peripheral chemoreceptor sensing of changes in PaCO₂/PaO₂ is rapid, unlike the prolonged circulation delay in CHF)
• Increases in severity and frequency with increasing altitude above 3000 m
• Gender differences: women have fewer events than men at equivalent altitudes (3400 m and 5400 m) and longer respiratory cycles
• At extreme altitude (>5500 m), paradoxically, apnea length and number decrease as high-frequency breathing dominates (greater central O₂-sensitive drive)
• Worsened by sleep (loss of wakefulness drive)
• Causes sleep fragmentation and arousals during the hyperpneic phase
• Oscillations in SaO₂ may increase susceptibility to HAPE and HACE
• Persists for >1 week even with acclimatization in many individuals; may gradually improve

Treatment

• Acetazolamide (carbonic anhydrase inhibitor): induces bicarbonate diuresis → metabolic acidosis → increases ventilatory drive → raises PaCO₂ above apneic threshold → reduces apneas. Standard first-line prevention. Dose: 125 mg at bedtime; also 125-250 mg q12h for AMS prevention.
• Supplemental oxygen: increases PaO₂ → reduces hypoxic drive → reduces the hyperpnea → raises PaCO₂ → narrows the oscillation

7. Neonatal and Infant Periodic Breathing

Normal Periodic Breathing of Infancy

• Pattern: cyclic episodes during sleep of brief apneic pauses (5-10 seconds) interrupting regular breathing, followed by a burst of rapid respiration
• Mechanism: immature central respiratory control in the brainstem; the respiratory oscillator has not yet achieved the stable gain characteristics of the mature system
• Clinical significance: generally benign; neurological complications do not occur unless hypoxic periods are prolonged and severe

Apnea of Prematurity (Pathological)

• Idiopathic (apnea of prematurity) - most common
• Intraventricular hemorrhage
• Seizures
• Upper airway obstruction / atelectasis
• Pneumonia, sepsis, meningitis
• Phrenic nerve paralysis
• Gastroesophageal reflux
• Hypovolemia
• Heart failure

• Caffeine (methylxanthine): stimulates central respiratory drive by adenosine receptor antagonism; standard therapy for apnea of prematurity. Early caffeine therapy (<3 days of life) is associated with better neurodevelopmental outcomes in infants born <29 weeks gestation.
• Supplemental oxygen
• CPAP

8. Summary: Types of Periodic Breathing

9. Key Pathophysiological Concepts - Summary